Skip to content
aiqbench takeMachine Learning

aiqbench analysis

This study demonstrates the practical application of Intrepid Labs' ANDROMEDA 1 algorithm in optimizing complex pharmaceutical formulations, successfully narrowing a vast design space to identify four viable candidates for long-acting injectables. By balancing multiple conflicting objectives such as viscosity and release kinetics, the research highlights how AI-driven multi-objective optimization can accelerate material science development beyond traditional trial-and-error methods. The findings underscore the growing role of machine learning in streamlining drug delivery system creation, moving from theoretical exploration to tangible formulation candidates.
Source coveringarXiv
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

Accelerating the Development of PLGA In Situ Forming Depots Through AI-Driven Multi-Objective Optimization

arXiv2 min read

arXiv:2610.08368v1 Announce Type: new Abstract: Developing long-acting injectable formulations requires the simultaneous optimization of drug loading, release kinetics, viscosity, injectability, stability and other objectives. To navigate this multidimensional space, Corbion and Intrepid combined Corbion's diverse PURASORB bioresorbable polymer library with Intrepid Labs' proprietary AI algorithm (ANDROMEDA 1) to develop in situ forming depots for a therapeutic peptide. Over approximately 15 weeks, 181 unique formulations spanning drug loadings of 6-12% w/w were prepared and characterized through broad design-space mapping and targeted multi-objective optimization. Four lead candidate formulations were identified at 6%, 9%, and 12% w/w drug loading. Each met the predefined viscosity and injectability criteria while providing distinct 30-day in vitro release profiles. The study evaluated polymers spanning a broad range of molecular weights, including commercially available PURASORB grades and new polymers under development by Corbion to expand its polymer toolbox. ANDROMEDA 1 identified that polymers with intermediate molecular weights provided a favorable balance between sustained release and solution viscosity. Together, these findings demonstrate how integrated polymer expertise and AI-driven optimization can rapidly identify differentiated formulation candidates, focus the development space, and establish a strong data-driven foundation for further optimization and in vivo evaluation.

Abstract:Developing long-acting injectable formulations requires the simultaneous optimization of drug loading, release kinetics, viscosity, injectability, stability and other objectives. To navigate this multidimensional space, Corbion and Intrepid combined Corbion's diverse PURASORB bioresorbable polymer library with Intrepid Labs' proprietary AI algorithm (ANDROMEDA 1) to develop in situ forming depots for a therapeutic peptide. Over approximately 15 weeks, 181 unique formulations spanning drug loadings of 6-12% w/w were prepared and characterized through broad design-space mapping and targeted multi-objective optimization. Four lead candidate formulations were identified at 6%, 9%, and 12% w/w drug loading. Each met the predefined viscosity and injectability criteria while providing distinct 30-day in vitro release profiles. The study evaluated polymers spanning a broad range of molecular weights, including commercially available PURASORB grades and new polymers under development by Corbion to expand its polymer toolbox. ANDROMEDA 1 identified that polymers with intermediate molecular weights provided a favorable balance between sustained release and solution viscosity. Together, these findings demonstrate how integrated polymer expertise and AI-driven optimization can rapidly identify differentiated formulation candidates, focus the development space, and establish a strong data-driven foundation for further optimization and in vivo evaluation.

Machine Learning (cs.LG); Artificial Intelligence (cs.AI)

arXiv:2610.08368 [cs.LG]

(or arXiv:2610.08368v1 [cs.LG] for this version)

https://doi.org/10.48550/arXiv.2610.08368 Focus to learn more arXiv-issued DOI via DataCite (pending registration)

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Full text under the publisher's open licence · 285 words

Related coverage